Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Diabetes & Metabolic Disorders
Published in: Journal of Diabetes & Metabolic Disorders 2/2020

01-12-2020 | Insulins | Research article

Mormodica charantia L. fruit and Genistein ameliorates type 2 diabetes in rats by preventing lipid accumulation, insulin resistance and enhancing beta cell function

Authors: Wusa Makena, Joseph O. Hambolu, James A. Timbuak, Uduak E. Umana, Abdullahi I. Iliya, Nathan I. Dibal

Published in: Journal of Diabetes & Metabolic Disorders | Issue 2/2020

Login to get access

Abstract

Purpose

The present study was aimed at evaluating the role of Momordica charantia L. fruit and Genistein on beta cell, insulin resistance/sensitivity and lipid profile in type 2 diabetic rats.

Methods

Thirty-five (35) albino rats were divided into seven (7) groups of 5 rats each comprising of five (5) non-diabetic and thirty (30) diabetic rats. Groups 1 and 2 served as the normal control and diabetic control groups respectively and received distill water, groups 3 and 4 received Mormodica charantia L. at 250 mg/kg and 500 mg/kg respectively. Groups 5 and 6 received Genistein at 10 mg/kg and 20 mg/kg respectively while group 7 received Metformin at 500 mg/kg the experiment lasted for four weeks. All the rats were euthanized at the end of the fourth week.

Results

Lipid profile, glucose and insulin levels were determined from the analysis of serum parameters and the histology of the pancreas. A significant reduction (p < 0.05) in blood glucose levels was noticed in rats that received Momordica charantia L. (MC) and genistein when compared with diabetic control rats. A significant decrease (p < 0.05) in cholesterol, triglyceride, low density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels were also noted in rats that received MC and Genistein when compared with the diabetic control rats. MC and Genistein significantly increased (P < 0.05) serum insulin level compared to the diabetic control rats. MC and Genistein significantly decreased (p < 0.05) homeostatic model assessment-insulin resistance (HOMA-IR) level compared with the diabetic control group. Pancreas of rats that received MC and Genistein showed regenerating beta-cells.

Conclusion

Momordica charantia L. fruit and Genistein were able to enhance beta cell function and prevent lipid accumulation and insulin resistance in type 2 diabetic rats.
Literature
1.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Position statement. Diabetes Care. 2014;37:81–90.
2.
Boland BB, Brown JC, Boland ML, Cann J, Sulikowski M, Hansen G, et al. Pancreatic b-cell rest replenishes insulin secretory capacity and attenuates diabetes in an extreme model of obese type 2 diabetes. Diabetes. 2019;68:131–40.PubMed
3.
Makena W, Hamman WO, Buraimoh AA, Dibal NI, Obaje SG. Therapeutic effects of balanitoside in streptozotocin-induced diabetic rats. J Taibah Univ Med Sci. 2018;13:402–6.PubMedPubMedCentral
4.
Engelgau MM, Geiss LS, Saaddine JB, Boyle JP, Benjamin SM, Gregg EW, et al. The evolving diabetes burden in the United States. Ann Intern Med. 2004;140:945–50.PubMed
5.
Gougeon R, Pencharz PB, Sigal RJ. Effect of glycemic control on the kinetics of whole body protein metabolism in obese subjects with non-insulin-dependent diabetes mellitus during iso and hypoenergetic feeding. Am J Clin Nutr. 1997;65:861–70.PubMed
6.
Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and DiabetesRelated complications. Phys Ther. 2008;88:1254–64.PubMedPubMedCentral
7.
Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev. 2002;23:201–29.PubMed
8.
9.
Kim MJ, Lim Y. Protective effect of short-term Genistein supplementation on the early stage in diabetes-induced renal damage. Mediators of Inflammation Mediators Inflamm. 2013;2013:1–14.
10.
Leahy JL, Hirsch IB, Peterson KA, Schneider D. Targeting β-cell function early in the course of therapy for type 2 diabetes mellitus. J Clinic Endocrinol Metab. 2010;95:4206–16.
11.
Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. International diabetes federation diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clinic Pract. 2018;138:271–81.
12.
Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clinic Pract. 2019;157:107843.
13.
Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017;389:2239–51.PubMed
14.
Kubola J, Siriamornpun S. Phenolic contents and antioxidant activities of bitter gourd (Momordica charantia L.) leaf, stem and fruit fraction extracts in vitro. Food Chem. 2008;110:881–90.PubMed
15.
Xie H, Huang S, Deng H, Wu Z, Ji A. Study on chemical components of Momordica charantia. Zhong Yao Cai. 1998;21:458–9.PubMed
16.
Raman A, Lau C. Anti-diabetic properties and phytochemistry of Momordica charantia L. (Cucurbitaceae). Phytomed. 1996;2:349–62.
17.
Grover JK, Yadav SP. Pharmacological actions and potential uses of Momordica charantia: a review. J Ethnopharmacol. 2004;93:123–32.PubMed
18.
Lu M, Wang R, Song X, Chibbar RC, Wang X, Wu L, et al. Dietary soy isoflavones increase insulin secretion and prevent the development of diabetic cataracts in streptozotocin-induced diabetic rats. Nutr. Res. 2008;28:464–71.PubMed
19.
Ahmed I, Adeghate E, Sharma AK, Pallot DJ, Singh J. Effects of Momordica charantia L. fruit juice on islet morphology in the pancreas of the streptozotocin-diabetic rat. Diabetes res. Clinic Pract. 1998;40:145–51.
20.
Wang ZQ, Zhang XH, Yu Y, Poulev A, Ribnicky D, Cefalu WT. Bioactives from bitter melon enhance insulin signaling and modulate acyl carnitine content in skeletal muscle in high-fat diet fed mice. J Nutr Biochem. 2011;22:1064–73.PubMedPubMedCentral
21.
Stephenson TJ, Setchell KDR, Kendall C, Jenkins WC, Anderson DJA, Fanti JWP. Effect of soy protein-rich diet on renal function inyoung adults with insulin-dependent diabetes mellitus. Clin Nephrol. 2005;64:1–11.PubMed
22.
Orgaard A, Jensen L. The effects of soy isoflavones on obesity. Exp Biol Med. 2008;233:1066–80.
23.
Lorke D. A new approach to practical acute toxicity. Arch Toxicol. 1983;54:275–87.PubMed
24.
El-Kordy EA, Alshahrani AM. Effect of genistein, a natural soy isoflavone on pancreatic β-cells of streptozotocin-induced diabetic rats: histological and immunohistochemical study. J Microsc Ultrastruct. 2015;3:108–19.PubMedPubMedCentral
25.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.PubMed
26.
Iliya IA, Mohammed B, Akuyam SA, Yaro JD, Bauchi ZM, Tanko M, et al. Immunohistochemical evaluation of the antidiabetic potentials of S-allyl-cysteine (garlic) and mangiferin (mango) in type 2 diabetic rat model. Sub-Saharan Afr J Med. 2016;3:25–31.
27.
Al Nahdi MT, John A, Raza H. Elucidation of molecular mechanisms of Streptozotocin-induced oxidative stress, apoptosis, and mitochondrial dysfunction in Rin-5F pancreatic β-cells. Oxidative Med Cell Longevity. 2017;2017:1–15.
28.
Wang Q, Jokelainen J, Auvinen J, Puukka K, Kiukaanniemi SK, Järvelin M, et al. Insulin resistance and systemic metabolic changes in oral glucose tolerance test in 5340 individuals: an interventional study. BMC Med. 2017;17:217.
29.
Boucher J, Kleinridders A, Ronald Kahn CR. Insulin receptor signaling in Normal and insulin-resistant states. Cold Spring Harb Perspect Biol. 2014;6:a009191.PubMedPubMedCentral
30.
Konsue A, Picheansoonthon C, Talubmook C. Fasting blood glucose levels and hematological values in Normal and Streptozotocin-induced diabetic rats of Mimosa pudica L. Extracts Pharmacogn J. 2017;9:315–22.
31.
Joseph B, Jini D. Antidiabetic effects of Momordica charantia L. (bitter melon) and its medicinal potency. Asian Pac J Trop Dis. 2013;3:93–102.PubMedCentral
32.
Nkambo W, Anyama NG, Onegi B. In vivo hypoglycemic effect of methanolic fruit extract of Momordica charantia L. Afr Health Sci. 2013;13:933–9.PubMedPubMedCentral
33.
Salehi B, Ata A, Kumar NVA, Sharopov F, Ramírez-Alarcón K, Ruiz-Ortega A, et al. Antidiabetic potential of medicinal plants and their active components. Biomolecules. 2019;9:551.PubMedCentral
34.
Tan SP, Kha TC, Parks SE, Roach PD. Bitter melon (Mormodica charanchia L.) bioactive composition and health benefits: a review. Food Rev Inter. 2016;32:181–202.
35.
Ummi R, Harijono ET, Edang S. Bioactive compound and nutritious characteristic of bitter melon fruit (Momordica charantia L.). RJOAS. 2018;7:308–16.
36.
Babu PVA, Si H, Fu Z, Zhen W, Liu D. Genistein prevents hyperglycemia-induced monocyte adhesion to human aortic endothelial cells through preservation of the cAMP signaling pathway and ameliorates vascular inflammation in obese diabetic mice. J Nutr. 2012;142:724–30.PubMedPubMedCentral
37.
Liu D, Zhen W, Yang Z, Carter JD, Si H, Reynolds KA. Genistein acutely stimulates insulin secretion in pancreatic beta-cells through a cAMP-dependent protein kinase pathway. Diabetes. 2006;55:165–6.
38.
Bakhtiari A, Hajian-Tilaki K, Omidvar S, Nasiri-Amiri F. Clinical and metabolic response to soy administration in older women with metabolic syndrome: a randomized controlled trial. Diabetol Metab Syndr. 2019;11:47.PubMedPubMedCentral
39.
Konya J, Sathyapalan T, Kilpatrick ES, Atkin SL. The Effects of Soy Protein and Cocoa with or without Isoflavones on Glycemic Control in Type 2 Diabetes. A Double-Blind, Randomized, Placebo-Controlled Study. Front Endocrinol. 2019;10:296.
40.
Xiao C, Dash S, Morgantini C, Hegele RA, Lewis GF. Pharmacological targeting of the Atherogenic dyslipidemia complex: the next frontier in CVD prevention beyond lowering LDL cholesterol. Diabetes. 2016;65:1767–78.PubMed
41.
Antwi-Baffour S, Kyeremeh R, Boateng SO, Annison L, Seidu MA. Haematological parameters and lipid profile abnormalities among patients with Type-2 diabetes mellitus in Ghana. Lipids Health Dis. 2018;17:283.PubMedPubMedCentral
42.
Bhowmik B, Siddiquee T, Mujumder A, Afsana F, Ahmed T, Mdala IA, et al. Serum lipid profile and its association with diabetes and Prediabetes in a rural Bangladeshi population. Int J Environ Res Public Health. 2018;15:1944.PubMedCentral
43.
Femlak M, Gluba-Brzózka A, Ciałkowska-Rysz A, Rysz J. The role and function of HDL in patients with diabetes mellitus and the related cardiovascular risk. Lipids Health Dis. 2017;16:207.PubMedPubMedCentral
44.
Vaisar T, Couzens E, Hwang A, Russell M, Barlow CE, DeFina LF, et al. Type 2 diabetes is associated with loss of HDL endothelium protective functions. PLoS One. 2018;13:e0192616.PubMedPubMedCentral
45.
Choi Y, Lee C, Lee K, Jung S, Lee B. Increased hepatic fatty acid uptake and esterification contribute to tetracycline-induced Steatosis in mice. Toxicol Sci. 2015;145:273–82.PubMed
46.
Temitope AG, Sheriff OL, Azeezat YF, Taofik A, Fatimah AI. Cardio-protective properties of Momordica charantia L.in albino rats. African J Sci Res. 2013;11:600–10.
47.
Zhou L, Xiao X, Zhang Q, Zheng J, Deng M. Maternal Genistein intake mitigates the deleterious effects of high-fat diet on glucose and lipid metabolism and modulates gut microbiota in adult life of male mice. Front Physiol. 2019;10:985.PubMedPubMedCentral
48.
Fu Z, Gilbert ER, Pfeiffer L, Zhang Y, Fu Y, Liu D. Genistein ameliorates hyperglycemia in a mouse model of nongenetic type 2 diabetes. Appl Physiol Nutr Metab. 2012;37:480–8.PubMedPubMedCentral
49.
Cerf ME. Beta cell dysfunction and insulin resistance. Front Endocrinol. 2013;4:1–12.
50.
Soares JMD, Leal AEP, Silva JC, Almeida JR, de Oliveira HP. Influence of flavonoids on mechanism of modulation of insulin secretion. Phcog Mag. 2017;13:639–46.PubMedPubMedCentral
51.
Fu Z, Zhang W, Zhen W, Lum H, Nadler J, Bassaganya-Riera J. Genistein induces pancreatic beta-cell proliferation through activation of multiple signaling pathways and prevents insulin-deficient diabetes in mice. Endocrinol. 2010;151:3026–37.
52.
Yin J, Li M, Xu L, Wang Y, Cheng H, Zhao X, et al. Insulin resistance determined by homeostasis model assessment (HOMA) and associations with metabolic syndrome among Chinese children and teenagers. Diabetol Metab Syndr. 2013;5:71.PubMedPubMedCentral
53.
Morimoto A, Tatsumi Y, Soyano F, Miyamatsu N, Sonoda N, Godai K, et al. Increase in homeostasis model assessment of insulin resistance (HOMA-IR) had a strong impact on the development of type 2 diabetes in Japanese individuals with impaired insulin secretion: the Saku study. PLoS One. 2014;9:e105827.PubMedPubMedCentral
54.
Atteritano M, Marini H, Minutoli L, Polito F, Bitto A, Altavilla D. Effects of the phytoestrogen genistein on some predictors of cardiovascular risk in osteopenic, postmenopausal women: a two-year randomized, double-blind, placebo-controlled study. J Clinic Endocrinol Metab. 2007;92:3068–75.
55.
Ha BG, Nagaoka M, Yonezawa T, Tanabe R, Woo JT, Kato H. Regulatory mechanism for the stimulatory action of genistein on glucose uptake in vitro and in vivo. J Nutr Biochem. 2012;23:501–9.PubMed
56.
DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. Diabetologia. 2010;53:1270–87.PubMedPubMedCentral
57.
Singh N, Gupta M. Regeneration of beta cells in islets of Langerhans of pancreas of alloxan diabetic rats by acetone extract of Momordica charantia (Linn.) (bitter gourd) fruits. Indian J Exp Biol. 2007;45:1055–62.PubMed
Metadata
Title
Mormodica charantia L. fruit and Genistein ameliorates type 2 diabetes in rats by preventing lipid accumulation, insulin resistance and enhancing beta cell function
Authors
Wusa Makena
Joseph O. Hambolu
James A. Timbuak
Uduak E. Umana
Abdullahi I. Iliya
Nathan I. Dibal
Publication date
01-12-2020
Publisher
Springer International Publishing
Published in
Journal of Diabetes & Metabolic Disorders / Issue 2/2020
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-020-00648-4

Other articles of this Issue 2/2020

Journal of Diabetes & Metabolic Disorders 2/2020 Go to the issue

Research article

The impact of type D personality on self-care of patients with type 2 diabetes: the mediating role of coping strategies

Research article

Evaluation of the effectiveness of Persian diabetes self-management education in older adults with type 2 diabetes at a diabetes outpatient clinic in Tehran: a pilot randomized control trial

Review article

Serum vitamin E level and gestational diabetes mellitus: a systematic review and meta-analysis

Review article

Therapeutic potential of melatonin as a chronobiotic and cytoprotective agent in diabetes mellitus

Review article

The effect of propolis on anthropometric indices and lipid profile: a systematic review and meta-analysis of randomized controlled trials

Study Protocol

The effectiveness of diabetes self-management education (DSME) on glycemic control among T2DM patients randomized control trial: systematic review and meta-analysis protocol
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits